Eli Lilly interview: Innovation and compliance, active ingredients

有效成分

March 10, 2016 | BY

Katherine Jo

Jane Huang, general counsel and VP of legal at Eli Lilly China, discusses the importance of R&D, communicating with HQ and employees, instilling a compliance culture and keeping up with the evolving healthcare industry. 礼来中国总法律顾问兼法务部副总裁黄洁莹探讨研发、与总部和员工沟通、培育合规文化以及与不断变化的医疗行业保持同步发展的重要性。

Can you describe your legal team? How many offices and facilities in China do you oversee?

I am the general counsel and VP of legal at Eli Lilly and Company. Lilly began building a locally-based legal team about 10 years ago; I joined in 2009. We currently have six lawyers on our team covering a wide range of issues related to general company law and healthcare.

We have our sales and commercial headquarters in Shanghai, as well as a separate R&D facility in the city, and a factory in Suzhou for manufacturing our licensed products. Our animal health arm, Elanco, recently acquired the animal health business from Novartis so we have also integrated that in China.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]